Merck & Co Resumes Islatravir HIV Studies After Safety Concerns, But Abandons PrEP Approach
Maintains Belief In Oral Long-Acting Regimen
Merck is trying to get its long-acting HIV program back on track, but is lagging behind GSK and Gilead • Source: Shutterstock 
